Biodesix (NASDAQ:BDSX) Receives “Outperform” Rating from William Blair

William Blair reiterated their outperform rating on shares of Biodesix (NASDAQ:BDSX) in a research note issued to investors on Tuesday,RTT News reports.

Biodesix Trading Up 1.0 %

NASDAQ:BDSX opened at $0.72 on Tuesday. Biodesix has a 52 week low of $0.64 and a 52 week high of $2.04. The firm has a 50 day moving average of $1.11 and a 200 day moving average of $1.41. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. The stock has a market capitalization of $104.74 million, a price-to-earnings ratio of -1.85 and a beta of 1.06.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. The business had revenue of $20.43 million during the quarter, compared to the consensus estimate of $19.92 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. As a group, sell-side analysts anticipate that Biodesix will post -0.35 earnings per share for the current fiscal year.

Insider Activity at Biodesix

In other Biodesix news, CEO Scott Hutton sold 83,660 shares of Biodesix stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $76,967.20. Following the completion of the transaction, the chief executive officer now owns 701,947 shares of the company’s stock, valued at approximately $645,791.24. The trade was a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 128,702 shares of company stock worth $118,406 over the last three months. Company insiders own 69.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BDSX. Balyasny Asset Management L.P. purchased a new position in Biodesix in the fourth quarter valued at $29,000. Barclays PLC increased its holdings in Biodesix by 1,140.5% in the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after buying an additional 21,179 shares in the last quarter. Boothbay Fund Management LLC purchased a new position in Biodesix in the fourth quarter valued at $52,000. MYDA Advisors LLC purchased a new position in Biodesix in the fourth quarter valued at $76,000. Finally, Cubist Systematic Strategies LLC increased its holdings in Biodesix by 385.9% in the fourth quarter. Cubist Systematic Strategies LLC now owns 51,024 shares of the company’s stock valued at $78,000 after buying an additional 40,524 shares in the last quarter. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.